New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new me...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/594 |
| _version_ | 1797855475849494528 |
|---|---|
| author | E. V. Morozova N. Yu. Tsvetkov M. V. Barabanshchikova K. S. Yurovskaya I. S. Moiseev |
| author_facet | E. V. Morozova N. Yu. Tsvetkov M. V. Barabanshchikova K. S. Yurovskaya I. S. Moiseev |
| author_sort | E. V. Morozova |
| collection | DOAJ |
| description | Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new methods of treatment remains urgent. Modern knowledge about the pathogenesis of the disease allows us to get an idea of the key pathways associated with oncogenesis and to develop new epigenetic methods of treatment.Aim. To consider the therapeutic approaches currently used in the treatment of patients with myelodysplastic syndrome of low and high risk groups, as well as to demonstrate the relevance of the search for new methods of targeted and immunotherapy. In this review, we highlight the achievements in the field of targeted therapy, in particular, the study of the biology of the TIM3 molecule and its ligands, new data from clinical trials of anti-TIM3 monoclonal antibodies. |
| first_indexed | 2024-04-09T20:24:18Z |
| format | Article |
| id | doaj.art-7094fcdabd40413eb30a3a802b1d8d83 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:24:18Z |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-7094fcdabd40413eb30a3a802b1d8d832023-03-30T20:15:14ZrusABV-pressОнкогематология1818-83462413-40232022-11-0117410611710.17650/1818-8346-2022-17-4-106-117472New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromeE. V. Morozova0N. Yu. Tsvetkov1M. V. Barabanshchikova2K. S. Yurovskaya3I. S. Moiseev4Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaCurrently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new methods of treatment remains urgent. Modern knowledge about the pathogenesis of the disease allows us to get an idea of the key pathways associated with oncogenesis and to develop new epigenetic methods of treatment.Aim. To consider the therapeutic approaches currently used in the treatment of patients with myelodysplastic syndrome of low and high risk groups, as well as to demonstrate the relevance of the search for new methods of targeted and immunotherapy. In this review, we highlight the achievements in the field of targeted therapy, in particular, the study of the biology of the TIM3 molecule and its ligands, new data from clinical trials of anti-TIM3 monoclonal antibodies.https://oncohematology.abvpress.ru/ongm/article/view/594myelodysplastic syndromehypomethylating agentstim3 |
| spellingShingle | E. V. Morozova N. Yu. Tsvetkov M. V. Barabanshchikova K. S. Yurovskaya I. S. Moiseev New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome Онкогематология myelodysplastic syndrome hypomethylating agents tim3 |
| title | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome |
| title_full | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome |
| title_fullStr | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome |
| title_full_unstemmed | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome |
| title_short | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome |
| title_sort | new perspectives in the treatment of patients with intermediate 2 and high risk myelodysplastic syndrome |
| topic | myelodysplastic syndrome hypomethylating agents tim3 |
| url | https://oncohematology.abvpress.ru/ongm/article/view/594 |
| work_keys_str_mv | AT evmorozova newperspectivesinthetreatmentofpatientswithintermediate2andhighriskmyelodysplasticsyndrome AT nyutsvetkov newperspectivesinthetreatmentofpatientswithintermediate2andhighriskmyelodysplasticsyndrome AT mvbarabanshchikova newperspectivesinthetreatmentofpatientswithintermediate2andhighriskmyelodysplasticsyndrome AT ksyurovskaya newperspectivesinthetreatmentofpatientswithintermediate2andhighriskmyelodysplasticsyndrome AT ismoiseev newperspectivesinthetreatmentofpatientswithintermediate2andhighriskmyelodysplasticsyndrome |